Oncology & Cancer

Blood cancer precursor found in 9/11 firefighters

A study in today's issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead ...

Oncology & Cancer

A first: All respond to gene therapy in a blood cancer study

Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that's on the rise. Although it's early and the study is small—35 people—every patient responded and all ...

Oncology & Cancer

New treatments to extend life for multiple myeloma patients

Multiple myeloma is a cancer of the plasma cells that reside inside bone marrow. Plasma cells produce certain proteins that build up the immune system. In abnormal quantities, these proteins damage the body and compromise ...

Oncology & Cancer

Researchers discover underlying cause of myeloma

Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published Feb. 10 in the New England Journal of Medicine, could fundamentally change ...

Oncology & Cancer

Multiple myeloma hides in bones like a wolf in sheep's clothing

Multiple myeloma uses a trick akin to a wolf in sheep's clothing to grow in and spread to new bone sites. By overexpressing Runx2, a gene that normally is a master regulator of bone formation, the cells of this largely incurable ...

Oncology & Cancer

Weight loss may help prevent multiple myeloma

New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood.

page 1 from 19

Multiple myeloma (from Greek myelo-, bone marrow), also known as plasma cell myeloma or Kahler's disease (after Otto Kahler), is a cancer of plasma cells, a type of white blood cell normally responsible for the production of antibodies. Collections of abnormal cells accumulate in bones, where they cause bone lesions (abnormal areas of tissue), and in the bone marrow where they interfere with the production of normal blood cells. Most cases of myeloma also feature the production of a paraprotein, an abnormal antibody that can cause kidney problems and interferes with the production of normal antibodies leading to immunodeficiency. Hypercalcemia (high calcium levels) is often encountered.

Myeloma is diagnosed with blood tests (protein electrophoresis, peripheral blood smear), microscopic examination of the bone marrow (bone marrow biopsy), and radiographs of commonly involved bones. Myeloma is generally thought to be incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Newer drugs, such as lenalidomide and bortezomib, are often used in more advanced disease. Radiation therapy is sometimes used to treat bone lesions that are causing symptoms.

The disease develops in 1–4 per 100,000 people per year. It is more common in men, and for yet unknown reasons is twice as common in African Americans as it is in white Americans. With conventional treatment, the prognosis is 3–4 years, which may be extended to 5–7 years or longer with advanced treatments. Multiple myeloma is the least common hematological malignancy (14%) and constitutes 1% of all cancers.

This text uses material from Wikipedia licensed under CC BY-SA